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Abstract
Background: Although National Cholesterol Education Program (NCEP), International Diabetes
Federation (IDF), American Heart Association and National Heart, Lung and Blood Institute (AHA/
NHLBI), World Health Organization (WHO), and the European Group for the Study of Insulin
Resistance (EGIR) definitions of metabolic syndrome (MetS) have been commonly used by studies,
little is known about agreement among these five definitions. We examined the agreement among
these five definitions and explored their relationship with risk factors of cardiovascular disease in
a Taiwan population.
Methods: A total of 1305 subjects aged 40 years and over in Taiwan were analyzed. Biomedical
markers and anthropometric indices were measured. Agreement among definitions was
determined by the kappa statistic. Logistic regression models were fit to estimate the odds of a high
cardiovascular risk group for five definitions of MetS.
Results: The agreement among the NCEP, IDF, and AHA/NHLBI definitions was from substantial
to very good, and agreement between the WHO and EGIR definitions was also substantial. All MetS
definitions were significantly associated prevalence of microalbuminuria, elevated highly sensitive
CRP (hs-CRP), and arterial stiffness only in women. In men, MetS by NCEP and AHA/NHLBI was
associated with elevated level of hs-CRP and arterial stiffness. MetS by WHO and EGIR were
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significantly associated with microalbuminuria. And MetS by WHO was the only MetS definition
that significantly associated with prevalence of arterial stiffness (OR: 2.75, 95% CI: 1.22-6.19).
Conclusions: The associations of these five definitions with cardiovascular risk factors were
similar in women, and it was evident that the five definitions performed better in women than in
men, with higher ORs observed in relation to arterial stiffness, elevated hs-CRP, and higher
Framingham risk scores.
Background
Metabolic syndrome (MetS) has been shown to increase
the risk of CVD mortality and all-cause mortality [1-3].
World Health Organization (WHO) [4] was the first to
propose criteria for the diagnosis of MetS, followed by
European Group for the Study of Insulin Resistance
(EGIR) [5]. In WHO and EGIR definitions, the presence of
insulin resistance was a prerequisite. National Cholesterol
Education Program (NCEP) Adult Treatment Panel III
(ATP-III) assigned MetS as a secondary target for interven-
tion [6]. In 2005, the International Diabetes Federation
(IDF) presented a MetS definition [7], in which central
obesity was the prerequisite and different cut-off values
for waist circumference were introduced for different eth-
nic groups. The American Heart Association and the
National Heart, Lung and Blood Institute (AHA/NHLBI)
modified the NCEP criteria by decreasing the glucose cut-
off from 110 to 100 mg/dl [8]. Although these definitions
have been commonly used by studies, little is known
about agreement among these five definitions of MetS,
especially the data in the AHA/NHLBI definition.
The value of MetS in health care contexts derives in large
part from its potential to reduce the risk of CVD by treat-
ing the disease. One way to understand which MetS defi-
nitions are more useful in practice is to examine the
relationships between these MetS definitions and CVD
risk factors. Some factors have been shown to be associ-
ated with an increased risk of CVD. Microalbuminuria is
one of the strongest predictors of glomerular filtration rate
decline, and it is associated with a higher risk of cardiovas-
cular disease and mortality [4,9]. Several cross-sectional
studies for Asians had been conducted to examine the
relationship of metabolic syndrome with microalbu-
minuria in senior citizens of rural Japanese [10], in dia-
betic Japanese patients [11], in urban Chinese residents
aged 40 years and over [12], in a Korean adults seeking
health check-up [13]. Arterial stiffness and peripheral vas-
cular disease (PVD) are two major underlying pathophys-
iologies of arterial disease and they are the primary cause
of CVD [14]. The effect of MetS defined by NECP, IDF, or
AHA/NHLBI criteria on arterial stiffness have been exam-
ined in Japanese [15-18], in Korean [19], and in Chinese
[20] by cross-sectional studies. Highly sensitive C-reactive
protein (hs-CRP) is a marker of systemic inflammation in
the body. Mild chronic elevations of hs-CRP concentra-
tions are independently predictive of future cardiovascu-
lar events [21,22]. The association of hs-CRP with MetS
has been explored in a study of 179 middle-aged Chinese
men with a family history of diabetes from a university
teaching hospital [23]. The Framingham Risk Scoring Sys-
tem is an index of the 10-year risk of fatal and nonfatal
CVD. The effect of the diagnosis of MetS using NECP,
WHO and IDF criteria on Framingham risk score have
been examined in Korean subjects who seek for physical
check-up [24]. The present study seeks to extend existing
research by examining the relationship between various
MetS definitions and these cardiovascular risk factors
simultaneously.
We posed two questions in the present research: what is
the estimate of agreement among the various MetS defini-
tions? Which MetS definitions are associated with the risk
factors for CVD.
Methods
Study population
This was a cross-sectional epidemiological study based on
data from the Taichung Community Health Study. A total
of 2,359 residents aged 40 and over in Taichung City, Tai-
wan, participated in October 2004. A two-stage sampling
design was used, with a sampling rate proportional to size
within each stage. At each stage, simple random sampling
was used. In the first stage of sampling, the sampling unit
was Li (administrative units) and the selection probability
for Li was set at 0.125. A total of 39 Lis were randomly
selected from 8 city districts. In the second stage, 110 indi-
viduals were randomly selected from each sample Li. A
total of 4280 individuals were selected and 750 individu-
als who were not eligible were excluded. A total of 3,530
subjects were eligible, and 2,359 agreed to participate
with an overall response rate of 66.83%. The detailed
methodology has been described elsewhere
[12,20,25,26].
Insulin levels only were measured in the first 1305 sub-
jects and they were analyzed in the current analysis. This
study was approved by the Human Research Committee
of China Medical University Hospital. Written informed
consent was obtained from each participant.BMC Public Health 2009, 9:484 http://www.biomedcentral.com/1471-2458/9/484
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Data collection
Anthropometric measurements were obtained from the
complete physical examination. Weight and height were
measured on an autoanthropometer (super-view, HW-
666), with subjects shoeless and wearing light clothing.
Body mass index (BMI) was derived from the formula of
weight (kg) ÷ (height)2 (m2). With the participant stand-
ing, waist circumference was measured midway between
the superior iliac crest and the costal margin. Percent body
fat mass (%FM) was assessed by conventional tetrapolar
bioelectrical impedance analysis using the Tanita BC-418
MA Impedanciometer (Tanita Corp., Tokyo, Japan) [27].
Blood pressure was measured using an electronic device
(COLIN, VP-1000, Japan).
The measurement of brachial-ankle pulse wave velocity
(baPWV) and the ankle-brachial index (ABI) were deter-
mined using an automatic waveform analyzer (VP-1000;
Colin Co., Komaki, Japan) with well-documented validity
and reproducibility (coefficient of variation [CV] = 3.31%
and reproducibility coefficient = 0.947). Higher baPWV
values indicated more severe arterial stiffness. Lower ABI
values indicated more severe PVD. High baPWV was
defined as a value higher than 1,400 cm/s, whereas an ABI
index <0.9 was considered the presence of PVD [28].
Blood was drawn with minimal trauma from an antecu-
bital vein in the morning, after a 12-hour overnight fast-
ing, and was sent for analysis within four hours of
collection. Biochemical markers such as fasting plasma
glucose, high-density lipoprotein cholesterol (HDL-C),
triglyceride, urine albumin and creatinine were analyzed
by a biochemical autoanalyzer (Beckman Coluter Syn-
chron system, Lx-20, Fullerton, CA, USA) at the Clinical
Laboratory Department of China Medical University Hos-
pital. Plasma cholesterol and triglyceride levels were
determined by an enzymatic colorimetric method. The
HDL-C level was measured by a direct HDL-C method and
the low-density lipoprotein cholesterol (LDL-C) level was
measured by a direct LDL-C method, too. The serum insu-
lin level was measured by a commercial enzyme-linked
immunosorbent assay kit (Diagnostic Products, Los Ange-
les, CA). The interassay CV for insulin was 8.7% and the
intra-assay CV was 3.4%. Insulin sensitivity was estimated
with a Homeostasis Model Assessment (HOMA-IR) equa-
tion. The HOMA-IR equals fasting serum insulin (μU/ml)
times fasting plasma glucose (mmol/l) divided by 22.5
[29]. Hs-CRP levels were measured by nephelometry, a
latex particle-enhanced immunoassay (TBA-200FR,
Tokyo, Japan). The interassay and intraassay CVs were
<2.0% and <1.9%, respectively. The lower detection limit
of the assay was 0.1 mg/L. The urinary albumin-to-creati-
nine ratio (ACR) in the morning urine sample was used as
a marker of the albumin excretion rate. Urinary creatinine
(Jaffe's kinetic method) and albumin (colorimetyl brom-
cresol purple) were measured by an autoanalyzer. The
interassay precision coefficient of variation was <3.0% for
both creatinine and albumin concentrations. Urinary ACR
ranging from 30 mg g-1 creatinine to 300 mg g-1 creati-
nine was defined as microalbuminuria [30].
Using the Framingham risk score based on the LDL-C
level [31], the estimated total coronary heart disease risk
over a 10-year period for every individual was calculated.
Data on sociodemographic characteristics, including gen-
der, age, smoking, drinking, physical activity, occupa-
tional activity, menopausal status, family history of
cardiovascular-related diseases, physician-diagnosed dis-
eases, and medication history were collected when the
participants underwent a complete physical examination.
The metabolic syndrome
Table 1 shows the criteria of the five MetS definitions stud-
ied. An Asian modification of the NCEP ATP-III definition
of MetS was used [32]. For WHO definition, we used
HOMA-IR to define insulin resistance. A similar modifica-
tion was used in previous studies [33,34]. We defined the
subjects in the highest quartile of the HOMA-IR distribu-
tion as insulin resistant [5]. The cutoff value of HOMA-IR
for non-diabetic subjects was 2.53 in this study and the
corresponding cutoff value of EGIR defined insulin resist-
ance was 10.40 μU/ml or 74.6 pmol/L. For medications,
they have to be prescribed by their physicians. For hyper-
tension, there are 4 types of treatment: angiotension II
converting enzyme inhibitor (ACEI), angiotensis II recep-
tor blocker, calcium channel blocker, and diuretics. For
low HDL and raised triglycerides, there are 4 types of treat-
ment: statins, bile acid sequestrants, nicotinic acid, and
fibric acids.
Statistical analysis
Continuous variables were reported as mean ± standard
deviation (SD) and categorical variables were reported as
percentages. Agreement between the five definitions of
MetS was determined using the kappa statistic (κ). The
level of agreement was considered poor with 0.20, fair
with κ = 0.21-0.40, moderate with κ = 0.41-0.60, substan-
tial with κ = 0.61-0.80, and very good with κ > 0.80 [35].
Logistic regression models were fit to estimate the odds of
high cardiovascular risk group for five definitions of MetS.
The high risk groups for %FM, hs-CRP, and Framingham
risk scores were determined by the upper quartile of their
distribution. All reported p values were those of two-sided
tests; statistical significance was set at p < 0.05. All analy-
ses were performed using SAS version 9.1 (SAS Institute
Inc, Cary, NC).
Results
The distributions of sociodemographic, anthropometric
and biochemical characteristics and prevalence of meta-BMC Public Health 2009, 9:484 http://www.biomedcentral.com/1471-2458/9/484
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bolic syndrome according to 5 definitions for all study
subjects, and according to gender are summarized in
Table 2. Agreement among the five definitions of MetS is
shown in Table 3. Agreement among the NCEP ATP-III,
IDF, and AHA/NHLBI definitions was from substantial to
very good (κ: 0.63-0.84 for men and 0.68-0.85 for
women), and that between the WHO and EGIR defini-
tions was also substantial (κ: 0.64 for men and 0.65 for
women). Agreement between NCEP ATP-III, IDF or AHA/
NHLBI and WHO or EGIR definitions was from fair to
moderate for both men and women.
The adjusted odds ratios (ORs) of the high risk group for
cardiovascular risk factors according to each definition of
MetS are shown in Table 4. All MetS definitions were sig-
nificantly associated with prevalence of high %FM and
high Framingham risk scores in both men and women. In
men, MetS by NCEP, AHA and WHO were associated with
an increase prevalence of arterial stiffness and hs-CRP. In
addition, MetS by NCEP, AHA, WHO and EGIR were sig-
nificantly associated with microalbuminuria, and MetS by
the WHO was the only MetS definition that significantly
associated with PVD. In women, all MetS definitions were
significantly associated with a prevalence of microalbu-
minuria, arterial stiffness, higher % FM, and elevated hs-
CRP, except for the EGIR with microalbuminuria. In men,
MetS of all definitions had larger ORs with high %FM
than with the other CVD risk factors, while in women,
MetS had larger ORs with high %FM and Framingham risk
scores than with the other CVD risk factors.
In additional file 1 Table S1 shows the relationships
between cardiovascular risk factors and components of
metabolic syndrome according to five definitions. In men,
most of components were associated with significant
adjusted OR in a similar way with the exception of obesity
component of WHO with arterial stiffness, obesity com-
ponent of EGIR with elevated hs-CRP, raised TG compo-
nent of NCEP/IDF/AHA/WHO with elevated hs-CRP,
raised blood pressure of NCEP/IDF/AHA with PVD, raised
fasting glucose of IDF/AHA and WHO with elevated hs-
CRP. In women, most of components were also associated
with significant adjusted OR in a similar way with the
exception of obesity component of NCEP, IDF/AHA/EGIR
with arterial stiffness, raised TG component of EGIR with
PVD and higher %FM, low HDL-cholesterol of NCEP/
IDF/AHA with arterial stiffness and higher %FM, raised
fasting glucose of NCEP/EGIR and WHO with higher
%FM and elevated hs-CRP.
Discussion
Our data show the kappa agreement between the defini-
tions not considering insulin measurement (NCEP, AHA/
NHLBI, or IDF) and the definitions requiring insulin
Table 1: Definitions of metabolic syndrome according to the NCEP ATP III, IDF, AHA, WHO, and EGIR criteria
Definition of Metabolic Syndrome (MetS)
NCEP IDF AHA WHO EGIR
Definition of MetS Any 3 of 5 criteria 
listed below
Increased waist plus 
any of 2 of other 4 
criteria
Any 3 of 5 criteria 
listed below
IFG, IGT, or IR plus 2 
of other 5 criteria
Insulin in top 25% plus 
2 of other 4 criteria
BMI (kg/m2) - -- -- -> 3 0 - -
Abdominal obesity 
(men/women)
Waist >90/80 Waist 90/80 Waist 90/80 Waist-to-hip ratio 
>0.9/0.85
Waist 94/80
Triglycerides (nmol/L) 1.7 or drug 
treatment for this lipid 
abnormality
1.7 or drug 
treatment for this lipid 
abnormality
1.7 or drug 
treatment for this lipid 
abnormality
1.7 or drug 
treatment for this lipid 
abnormality
>2.0 or drug 
treatment for this lipid 
abnormality
HDL cholesterol 
(nmol/L) (men/
women)
<1.0/1.3 or drug 
treatment for this lipid 
abnormality
<1.0/1.3 or drug 
treatment for this lipid 
abnormality
<1.0/1.3 or drug 
treatment for this lipid 
abnormality
<0.9/1.0 or drug 
treatment for this lipid 
abnormality
<1.0 or drug 
treatment for this lipid 
abnormality
Blood pressure 
(mmHg)
130/85 or drug 
treatment for 
hypertension
130/85 or drug 
treatment for 
hypertension
130/85 or drug 
treatment for 
hypertension
140/90 or drug 
treatment for 
hypertension
140/90 or drug 
treatment for 
hypertension
H O M A - I R - -- -- -> 2 . 5 3 - -
Fasting glucose 
(nmol/L)
6.1 5.6 5.6 6.1 6.1
Fasting insulin 
(pmol/L)
-- -- -- -- >74.6 (Top 25%)
Urinary albumin 
excretion
-- -- -- 30 mg/g creatinine --
National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP-III), International Diabetes Federation (IDF), American Heart 
Association and National Heart Lung and Blood Institute (AHA/NHLBI), World Health Organization (WHO), European Group for the Study of 
Insulin Resistance (EGIR), metabolic syndrome (MetS), body mass index (BMI), high-density lipoprotein (HDL), homeostasis model assessment of 
insulin resistance (HOMA-IR), insulin resistance (IR).BMC Public Health 2009, 9:484 http://www.biomedcentral.com/1471-2458/9/484
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measurement (WHO or EGIR) ranged from 0.33 to 0.46
in men and from 0.34 to 0.42 in women, and was from
fair to moderate, similar to previous findings [34,36].
AHA/NHLBI was not evaluated in Can's and Dekker's
work and IDF was not evaluated in Dekker's work. But the
agreement between IDF and WHO definitions in our
study (κ = 0.37) was much lower than in Guerrero-
Romero's work (κ = 0.51) [37]. We found a substantial
agreement (κ = 0.67) between NCEP and IDF definitions,
much lower than those in Can's and Guerrero-Romero's
studies (both κ = 0.87), but higher than that (κ = 0.54) in
the Korean Health and Examination Survey [38].
Our study identified similarities among the five defini-
tions of MetS, but also revealed differences. In men, all
definitions were associated with high %FM and high
Framingham risk scores. The only definitions associated
with microalbuminuria were those considering insulin
resistance (WHO and EGIR criteria), and WHO definition
was the only predictor of PVD. On the other hand, the
NCEP ATP III and AHA definitions, which did not con-
sider insulin resistance, were associated with arterial stiff-
ness and elevated hs-CRP. IDF definition was not
correlated with arterial stiffness or elevated hs-CRP, possi-
bly due to its prerequisite factor. In general, the associa-
tions of these five definitions with cardiovascular risk
factors were similar in women, and it was evident that the
five definitions in women performed better than in men,
with higher ORs observed in relation to arterial stiffness,
Table 2: Distributions of sociodemographic, anthropometric and biochemical characteristics, and prevalence of metabolic syndrome 
according to 5 definitions for all study subjects, and according to gender
Mean (SD)
Overall
(N = 1305)
Men
(N = 633)
Women
(N = 672)
Age (years) 55.99 (11.25) 57.71 (12.23) 54.37 (9.98)
Smoking (%)† 198 (15.18) 175 (27.65) 23 (3.43)
Drinking (%)† 314 (24.08) 242 (38.23) 72 (10.73)
Betel nut chewing (%)† 40 (3.07) 39 (6.18) 1 (0.15)
Exercise (%)†a 865 (66.33) 423 (66.93) 442 (65.77)
Body mass index (kg/m2) 24.35 (3.26) 24.87 (3.11) 23.85 (3.33)
Waist circumference (cm) 81.71 (9.87) 86.74 (8.55) 76.98 (3.61)
Waist-to-hip ratio 0.85 (0.07) 0.89 (0.05) 0.81 (0.06)
Fasting blood glucose (mmol/l) 5.74 (1.53) 5.87 (1.53) 5.61 (1.53)
Fasting insulin (pmol/l) 60.92 (48.50) 64.65 (48.38) 57.40 (48.43)
HOMA-IR 2.06 (2.23) 2.43 (2.13) 2.11 (2.30)
Triglyceride (mmol/l) 1.32 (0.99) 1.49 (1.16) 1.16 (0.76)
HDL-cholesterol (mmol/l) 1.20 (0.34) 1.07 (0.28) 1.31 (0.34)
LDL-cholesterol (mmol/l) 3.34 (0.88) 3.37 (0.87) 3.32 (0.89)
Diastolic blood glucose (mmHg) 78.37 (11.94) 81.77 (10.82) 75.14 (12.05)
Systolic blood glucose (mmHg) 133.68 (20.68) 136.51 (19.53) 131.02 (21.38)
Hypertension (%)† 354 (27.21) 189 (29.91) 165 (24.66)
Family history of diabetes (%)† 330 (25.10) 157 (24.84) 173 (25.74)
Microalbuminuria (%/ACR 30 μg/min)† 278 (21.38) 120 (18.99) 158 (23.65)
PVD†b 86 (6.59) 37 (5.85) 49 (7.29)
Arterial stiffness†c 838 (64.76) 455 (72.45) 383 (57.51)
%FM 31.59 (7.62) 26.45 (5.50) 36.40 (6.02)
Hs-CRP (mg/L) 0.25 (0.50) 0.26 (0.54) 0.23 (0.46)
Metabolic syndrome by NCEP ATP-III 410 (31.42) 226 (35.70) 184 (27.38)
Metabolic syndrome by IDF 328 (25.13) 167 (26.38) 161 (23.96)
Metabolic syndrome by AHA 501 (38.39) 275 (43.44) 226 (33.63)
Metabolic syndrome by WHO 246 (18.85) 154 (24.33) 92 (13.69)
Metabolic syndrome by EGIR* 203 (15.56) 123 (19.43) 80 (11.90)
homeostasis model assessment of insulin resistance (HOMA-IR), high-density lipoprotein (HDL), low-density lipoprotein (LDL), albumin-creatinine 
ratio (ACR), ankle-brachial index (ABI), brachial-ankle pulse wave velocity (baPWV), percent body fat mass (%FM), peripheral vascular disease 
(PVD), highly sensitive C-reactive protein (hs-CRP), National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP-III), 
International Diabetes Federation (IDF), American Heart Association and National Heart Lung and Blood Institute (AHA/NHLBI), World Health 
Organization (WHO), European Group for the Study of Insulin Resistance (EGIR). †: n (%). *:A total of 1305 samples, includes 633 men and 672 
women. a: Participants reported they spent at least 20 minutes in any types of recreational activity at least 3 times per week for more than 6 
months. b: peripheral vascular disease (PVD): ankle-brachial index (ABI) < 0.9. c: arterial stiffness: brachial-ankle pulse wave velocity (baPWV) > 
1400 cm/s.BMC Public Health 2009, 9:484 http://www.biomedcentral.com/1471-2458/9/484
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elevated hs-CRP, and higher Framingham risk scores, and
more ORs significantly related to microalbuminuria.
The reason why IDF definition correlated less well with
arterial stiffness or elevated hs-CRP, compared to NCEP
ATP III or AHA/NHLBI definition, may be that central
obesity is a prerequisite factor of IDF definition. Central
obesity is believed to be associated with insulin resistance
and has been suggested to induce insulin resistance and
hyperinsulinemia, owing to the influence of free fatty
acids, derived from visceral fat, on the liver [39]. Khoo et
al. [40] determined the effect of the presence of central
obesity on insulin resistance and other cardiovascular risk
factors. They found that central obesity is important for
the identification of individuals with insulin resistance
and glucose intolerance; whereas AHA/NHLBI definition
is more appropriate in identifying those at increased risk
of cardiovascular disease. A significant proportion of indi-
viduals in their population (ranging from 10% to 13% in
men and 2% to 4% in women) exhibited multiple fea-
tures of MetS in the absence of central obesity. In our
study, this proportion was even higher (14.75% in men
Table 3: Agreement between each definition of the metabolic syndrome.a
NCEP IDF AHA WHO
Men
IDF 0.63 (0.57-0.70)
AHA 0.84 (0.80-0.88) 0.64 (0.58-0.69)
WHO 0.49 (0.42-0.56) 0.40 (0.32-0.48) 0.43 (0.36-0.49)
EGIR 0.44 (0.37-0.52) 0.47 (0.39-0.55) 0.37 (0.31-0.44) 0.64 (0.56-0.71)
Women
IDF 0.68 (0.62-0.75)
AHA 0.85 (0.81-0.90) 0.77 (0.71-0.82)
WHO 0.49 (0.42-0.57) 0.43 (0.35-0.51) 0.43 (0.36-0.50)
EGIR 0.40 (0.32-0.48) 0.40 (0.32-0.49) 0.37 (0.30-0.43) 0.65 (0.57-0.74)
a: kappa statistics and their 95% confidence interval were presented.
National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP-III), International Diabetes Federation (IDF), American Heart 
Association and National Heart Lung and Blood Institute (AHA/NHLBI), World Health Organization (WHO), European Group for the Study of 
Insulin Resistance (EGIR).
Table 4: The adjusted OR for metabolic syndrome of each studied definition associated with cardiovascular risk factors
Adjusted OR (95% CI)a
Men (N = 633) Women (N = 672)
NCEP IDF AHA WHO EGIR NCEP IDF AHA WHO EGIR
Microalbu
minuria
1.99**
(1.31-3.03)
1.51
(0.97-2.35)
1.64*
(1.08-2.50)
4.44***
(2.85-6.91)
2.62***
(1.49-4.60)
2.21***
(1.47-3.32)
2.29***
(1.51-3.48)
2.26***
(1.52-3.38)
4.16***
(2.57-6.73)
1.80
(0.99-3.29)
PVD 1.29
(0.65-2.59)
1.48
(0.72-3.20)
1.36
(0.69-2.70)
2.24*
(1.11-4.55)
2.17
(0.92-5.10)
1.68
(0.83-3.40)
1.20
(0.57-2.54)
1.17
(0.58-2.33)
1.34
(0.56-3.19)
1.12
(0.38-3.33)
Arterial 
stiffness
3.07***
(1.92-4.92)
1.27
(0.79-2.03)
2.90***
(1.88-4.48)
1.95*
(1.15-3.29)
1.40
(0.80-2.47)
3.72***
(2.23-6.20)
3.18***
(1.88-5.40)
3.99***
(2.50-6.35)
6.61***
(2.93-
14.92)
4.63**
(2.02-
10.63)
Higher 
%FM
6.93***
(4.66-
10.28)
11.29***
(7.39-
17.23)
5.55***
(3.73-8.26)
5.58***
(3.72-8.37)
10.76***
(6.35-
18.23)
4.56***
(3.05-6.82)
8.88***
(5.78-
13.65)
4.31***
(2.90-6.42)
3.24***
(2.01-5.23)
8.30***
(4.47-
15.41)
Elevated 
hs-CRP
1.78**
(1.23-2.59)
1.15
(0.77-1.73)
1.71**
(1.19-2.48)
1.66*
(1.11-2.50)
1.45
(0.87-2.42)
3.09***
(2.07-4.62)
2.25**
(1.49-3.39)
2.63***
(1.78-3.89)
4.42***
(2.73-7.15)
4.14***
(2.28-7.52)
Higher risk 
scoresb
4.13***
(2.62-6.51)
2.60***
(1.64-4.13)
3.82***
(2.44-5.98)
4.65***
(2.84-7.62)
2.79***
(1.48-5.26)
9.51***
(5.94-
15.21)
4.77***
(3.00-7.59)
10.25***
(6.54-
16.07)
10.57***
(5.48-
20.42)
5.54***
(2.73-
11.27)
aLogistic regression adjusted for age, smoking, alcohol drinking, betel nut chewing, low income, education.
bFramingham risk score31 ; microalbuminuria: albumin-creatinine ratio (ACR) >30 mg g-1 creatinine, peripheral vascular disease (PVD): ankle-
brachial index (ABI) <0.9; arterial stiffness: brachial-ankle pulse wave velocity (baPWV) >1400 cm/s; higher percent body fat mass (%FM) greater 
than the cutoff value of 3th quartile; elevated highly sensitive C-reactive protein (hs-CRP): greater than the cutoff value of 3th quartile; higher risk 
scores: Framingham risk score greater than the cutoff value of 3th quartile.
*: p < 0.05; **: p < 0.01; ***: p < 0.001BMC Public Health 2009, 9:484 http://www.biomedcentral.com/1471-2458/9/484
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and 7.99% in women). These individuals would be diag-
nosed as having MetS according to NCEP ATP III or AHA/
NHLBI criteria, but not by IDF criteria. Thus, MetS accord-
ing to IDF criteria has lower prevalence. Under such con-
dition, IDF definition will have less power, which may
explain why IDF definition was less well correlated with
cardiovascular risk factors in our study and previous work.
One of the limitations of our study is that it was cross-sec-
tional and examined cardiovascular risk factors among
MetS definitions. Although many studies have compared
different definitions [34,36,38,41-50], only one has com-
pared more than four published definitions of MetS [36].
Instead of including the NCEP definition, Can's work
examined the American College of Endocrinology (ACE)
definition. In addition, microalbuminuria was not
counted as a component in the WHO definition in their
study. Although our study only provided cross-sectional
relationships between MetS and cardiovascular risk fac-
tors, no cross-sectional study has compared five published
definitions in relation to hs-CRP, arteriosclerosis, and
PVD. Another limitation of our study is that insulin sensi-
tivity was determined by HOMA-IR, and not the insulin
sensitivity index derived from the hyperinsulinemic eug-
lycemic clamp. Previous studies indicated that there
existed a moderate to strong relationship between the
HOMA-IR value and the insulin sensitivity index [51,52].
However, the insulin sensitivity index is not feasible for
epidemiologic studies involving large numbers of partici-
pants. In addition, we did not perform oral glucose toler-
ance testing, so we may not provide valid estimate for the
prevalence of MetS for the EGIR and WHO definitions by
included some patients with T2DM or excluding some
hyperglycemic cases that could be detected by glucose tol-
erance testing.
Conclusions
In conclusion, among the NCEP-ATP III, IDF, and AHA/
NHLBI definitions of MetS, the agreement among the def-
initions that do not require the measurement of insulin
levels are from substantial to very good agreement, and
the agreement between the WHO and EGIR definitions,
the definitions that require the measurement of insulin
sensitivity and fasting insulin levels, is substantial. Our
data suggest that different definitions of MetS were corre-
lated with all cardiovascular risk factors in women, but
with different cardiovascular risk factors in men. In men,
the modified NCEP ATP III and AHA/NHLBI (but not
IDF) definitions were associated with an elevated level of
hs-CRP and arterial stiffness independently of high-risk
lifestyle behaviors, but the WHO definition seems to be
more related to microalbuminuria and PVD. Since serum
insulin, hs-CRP, baPWV, ABI, and urinary albumin are rel-
atively costly measures compared with the other routine
biologic markers, they are not feasible to be collected in
everyday practice. Thus, our study findings provided new
insight for diagnosis of MetS using various definitions in
clinical practice.
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